CANMAT Medication Guidelines for Bipolar Disorder

Dr. Gregor Kowal German-Board Certified Consultant in Psychiatry on CANMAT Treatment Guidelines for Bipolar Disorder. Dr. Gregor Kowal is a German-Board Certified Consultant in Psychiatry and Psychotherapy. — Dr. Gregor Kowal is a German-Board Certified Consultant in Psychiatry and Psychotherapy. He graduated from the prestigious University of Heidelberg, Germany. Dr. Kowal has held leadership and teaching positions, serving as Head of Department and later as Medical Director at renowned psychiatric hospitals across Germany. He specializes in the treatment of various psychiatric conditions, including bipolar disorder

Bipolar disorder is a severe, recurring psychiatric illness that, when left untreated, can lead to significant social disadvantages, disability, and neurotrophic brain changes. Treatment goals include symptom remission during acute episodes, prevention of relapses, and neuroprotection.

Since 2018, new studies, meta-analyses, and revisions of treatment recommendations from the Canadian Network for Mood and Anxiety Treatments (CANMAT) have been published for the management of patients with Bipolar Disorder. These recommendations are based on scientific studies and international guidelines.

For more information contact our consultant psychiatrist Dr. Kowal

Call CHMC

Contents hide

1 CHMC’s Use of CANMAT Guidelines for Bipolar Disorder

2 CANMAT Medication Recommendations for Bipolar Disorder

3 CANMAT Recommendation for Acute Mania

5 CANMAT-Recommened Medication for Relapse Prevention

6 Medication for Rapid Cycling

7 Treatment with Atypical Antipsychotics

8 Treatment with Antiepileptic Medication

9 CANMAT Guidelines for Bipolar Disorder. Summary

10 Read More About Bipolar Disorder

CHMC’s Use of CANMAT Guidelines for Bipolar Disorder

Despite the proven effectiveness of bipolar disorder medication, the CANMAT guidelines emphasize that a comprehensive treatment plan should combine both pharmacological and psychosocial strategies. This includes bipolar medication paired with psychotherapy, individual and group psychoeducation, family involvement, and, when necessary, supported employment.

At CHMC Dubai, we integrate these global standards into our bipolar disorder treatment, offering individualized plans that include bipolar disorder medication treatment and holistic care based on evidence-backed protocols. CHMC uses the CANMAT guidelines, containing the most comprehensive data and treatment options with medication for bipolar disorder.

CANMAT Medication Recommendations for Bipolar Disorder

Medication for bipolar disorder should suppress symptoms, prevent symptom recurrence, and have neuroprotective effects. Depending on the phase of bipolar disorder, treatment with medication can be categorized into acute therapy, continuation therapy, and relapse prevention.

CANMAT Recommendation for Acute Mania

Treatment for acute mania suggests monotherapy with lithium, valproate, or various atypical antipsychotics as the first-line options. Lithium continues to be the “gold standard” for treating bipolar disorders. It is the first-line option for acute mania and particularly for long-term treatment of bipolar disorders.

Combinations of a mood-stabilizing agent (lithium, valproate) with an atypical antipsychotic are also recommended due to their particularly pronounced efficacy. As a general rule, medications that were effective during the acute phase are also suitable for maintenance therapy.

CANMAT-Recommended Medication for Bipolar Depression

In bipolar depression, the best evidence supports monotherapy with quetiapine, followed by lithium and lurasidone. Combining a mood stabilizer or antimanic agent (e.g., lithium or atypical antipsychotics) with lamotrigine or an antidepressant, especially an SSRI or bupropion, is also recommended.

CANMAT-Recommened Medication for Relapse Prevention

The first-line options for relapse prevention are recommended: lithium, quetiapine, lamotrigine (primarily for preventing depressive episodes), aripiprazole (for preventing manic episodes), olanzapine, valproate, and asenapine. Also, the combinations of lithium and valproate and lithium or valproate with quetiapine can be used.

Aripiprazole and risperidone are recommended in combination with a mood-stabilizing agent. In relapse prevention, combinations of lithium or valproate with aripiprazole, risperidone, and lamotrigine are recommended. Lithium and valproate can also be combined with risperidone and aripiprazole as depot injections.

Medication for Rapid Cycling

A course of bipolar disorder with four or more episodes within one year is called “rapid cycling.” Treatment for rapid cycling is challenging. Hypothyroidism, use of antidepressants, or substance abuse are often associated with this course pattern.

Patients with rapid cycling seem to respond less well to antidepressants than other bipolar patients. The risk of depressive relapses is tripled in rapid cycling. The CANMAT guidelines recommend against the use of antidepressants in rapid cycling. Lithium and lamotrigine have shown antidepressant effects in controlled studies. For the long-term treatment of rapid cycling, the CANMAT guidelines recommend combination therapies with valproate and lithium.

Treatment with Atypical Antipsychotics

Atypical antipsychotics are also considered first-line options for mania, bipolar depression, and long-term treatment (especially quetiapine). Asenapine and paliperidone are newly recommended as monotherapy and in combination for the treatment of acute mania.

Treatment with Antiepileptic Medication

Anticonvulsants have differential efficacy for the manic and depressive poles. Valproate has an acute antimanic effect, while lamotrigine has a preventive effect against depression. Lamotrigine has been newly recommended for the acute treatment of bipolar depression.

CANMAT Guidelines for Bipolar Disorder. Summary

Epidemiological data shows that bipolar disorders typically persist lifelong. There is increasing evidence that bipolar disorder may be a neuroprogressive disease. Each relapse can lead to neurotrophic and inflammation-related changes in the grey and white matter of the brain. Such changes will cause neurocognitive deficits affecting memory and concentration and decrease the emotional modulation. Therefore, all patients with bipolar disorder require long-term therapy and relapse prevention.

A variety of pharmacological substances are available for the treatment of bipolar disorder. There are now several approaches to choose from, some of which are equally effective in clinical practice. Treatment guidelines for bipolar disorder vary widely and are not always uniform. CHMC uses the CANMAT guidelines, containing the most comprehensive data and treatment options for bipolar disorder.

The choice of therapy depends on the individual’s medical history, previous treatment experiences, and the specific characteristics of their symptoms and illness progression. In addition to medication, psychoeducational and psychosocial interventions are beneficial.